Details of the Drug
General Information of Drug (ID: DMP13VE)
| Drug Name |
ML9
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
ML-9 free base; UNII-LTJ3F5128V; 110448-31-2; LTJ3F5128V; CHEMBL429298; ML9; 1-[(5-chloro-1-naphthyl)sulfonyl]-1,4-diazepane; 1H-1,4-Diazepine, 1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-; Tocris-0431; ACMC-20mde5; BiomolKI_000043; AC1L1HOD; Lopac-C-1172; BiomolKI2_000008; Lopac0_000209; BSPBio_001271; GTPL4256; SCHEMBL2869228; CTK0D4761; CHEBI:93202; DTXSID00149246; ZINC402771; HMS1792O13; Bio1_000938; Bio1_001427; Bio1_000449; HMS3403O13; HMS1990O13; BDBM50216681; 1H-1,4-Diazepine, 1-((5-chloro-1-naphthalenyl)sulfonyl)hexahydro-)
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 324.8 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References


